» Articles » PMID: 18292504

Mitigation of Experimental Allergic Encephalomyelitis by TGF-beta Induced Foxp3+ Regulatory T Lymphocytes Through the Induction of Anergy and Infectious Tolerance

Overview
Journal J Immunol
Date 2008 Feb 23
PMID 18292504
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Stimulation of naive T lymphocytes in the presence of IL-2 and TGF-beta induces the regulatory transcription factor Foxp3, which endows the cells with regulatory functions. To better understand the properties and therapeutic potential of these induced regulatory T cells (iTreg), we examined their immunomodulatory properties in myelin oligodendroglial glycoprotein-induced experimental allergic encephalomyelitis (MOG-EAE). Adoptively transferred iTreg were as potent as natural Foxp3+ Treg in preventing EAE development, and were active both prophylactically and after priming. The iTreg migrated into the CNS in quantity, skewing the ratio of regulatory to effector T lymphocytes. IL-10-/- iTreg failed to suppress disease, demonstrating a critical role for iTreg IL-10 production in their therapeutic activity. MOG-specific T cells from iTreg treated animals were anergic. The cells failed to proliferate in response to Ag except in the presence of exogenous IL-2, and did not secrete or secreted reduced amounts of IL-2, IFN-gamma, and IL-17. MOG-specific T cells were not wholly unresponsive though, as they did secrete IL-10 after stimulation. To determine whether iTreg-mediated tolerance was infectious, fostering the development of T lymphocytes that could independently suppress EAE, we purged draining lymph node cells from MOG-immunized, iTreg treated mice of the administered iTreg, and transferred the remaining cells to Ag-inexperienced mice. The transferred cells were able to block EAE development. Thus iTreg are highly potent suppressors of autoimmune encephalomyelitis, and act in an IL-10 dependent manner both through the induction of anergy in effector T cells and through the infectious induction of protective T lymphocytes able to independently suppress disease development.

Citing Articles

Regulatory T cells in lung disease and transplantation.

Lao P, Chen J, Tang L, Zhang J, Chen Y, Fang Y Biosci Rep. 2023; 43(10).

PMID: 37795866 PMC: 10611924. DOI: 10.1042/BSR20231331.


Induced regulatory T cells suppress Tc1 cells through TGF-β signaling to ameliorate STZ-induced type 1 diabetes mellitus.

Zhou L, He X, Cai P, Li T, Peng R, Dang J Cell Mol Immunol. 2021; 18(3):698-710.

PMID: 33446887 PMC: 8027661. DOI: 10.1038/s41423-020-00623-2.


Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3 regulatory T cells.

Mannie M, DeOca K, Bastian A, Moorman C Cell Immunol. 2020; 355:104173.

PMID: 32712270 PMC: 7444458. DOI: 10.1016/j.cellimm.2020.104173.


Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.

Stark A, Davenport E, Patton D, Scudamore C, Vanhaesebroeck B, Veldhoen M J Immunol. 2020; 205(1):78-89.

PMID: 32414808 PMC: 7311201. DOI: 10.4049/jimmunol.2000043.


Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.

Horwitz D, Fahmy T, Piccirillo C, La Cava A Trends Immunol. 2019; 40(10):888-908.

PMID: 31601519 PMC: 7136015. DOI: 10.1016/j.it.2019.08.003.